Market Optimizer

Insulin Resistance Therapeutic Pipeline Review H2 2014 adds “Insulin Resistance – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Insulin Resistance’s therapeutic pipeline.


Dallas, TX -- (SBWIRE) -- 10/17/2014 -- This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

Insulin resistance (IR) is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin. The body produces insulin, but the cells in the body become resistant to insulin and are unable to use it as effectively, leading to hyperglycemia. Beta cells in the pancreas subsequently increase their production of insulin, further contributing to hyperinsulinemia. This often remains undetected and can contribute to a diagnosis of Type 2 Diabetes or latent autoimmune diabetes of adults.

Complete Report Available

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Order a Purchase copy

Insulin Resistance - Companies Involved in Therapeutics Development:

-GlaxoSmithKline plc
-Mochida Pharmaceutical Co., Ltd.
-Novartis AG
-Hadasit Medical Research Services & Development Ltd
-Genfit SA
-N-Gene Research Laboratories, Inc.
-AUS Bio Limited
-Thetis Pharmaceuticals LLC

Insulin Resistance - Drug Profiles:

GFT-505, BGP-15, BVS-857, Protein Kinase C Derived Peptides, MD-960, Drug to Activate AMPK Beta for Inflammation and Insulin Resistance, Small Molecule to Antagonize TRPV4, Drugs to Inhibit TRIP-Br2 for Metabolic Disorders, Small Molecule Targeting AMPD2 for Hypertension and Metabolic Disorders, Small Molecules to Inhibit DGAT-1 for Metabolic Disorders, Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular, Peptide for Obesity and Insulin Resistance, Englerin A, Small Molecule for Atherosclerosis and Insulin Resistance, Antisense Oligonucleotides Targeting ABHD6 for Gastrointestinal and Metabolic Disorders, SAR-088, Small Molecule for Hypertension and Insulin Resistance, TP-113, SERX-1, Small Molecules to Inhibit PARP for Immunology Oncology Cardiovascular and Metabolic Disorders, Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders.


- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Inquire for Discount
(This is a premium report priced at US$2000 for a single user License.)

Reasons to buy:

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Diabetes Therapeutics Market